Stem cell therapies may be relatively early stage, but that hasn’t stopped their developers from giving some serious thought to late stage issues like reimbursement and health economics.
About this Blog
BioWorld Perspectives is the official blog for news, analysis, debates, commentary and camaraderie related to the development of biotechnology drugs.
Subscribe to our Blog
Recent Posts
- History, Mystery, Gastronomy in the Mix in BioWorld’s 7th Annual Biotech Summer Reading List
- Oh, Give it Iressa! Nope: ‘Bad Pharma’ Firms Need to Tell More
- Patients Want More than Check-the-Box Experience
- Biotech’s White Knight (aka Serial Cheater) Gets Prison Time, Finally
- Where’s Superman When He’s Needed?
Categories
- Accelerated approval (3)
- acquisition (1)
- acute kidney injury (1)
- adcom (2)
- aging (1)
- AIDS (1)
- antibiotics (2)
- Antibody (2)
- Autism (1)
- Big pharma (28)
- bioethics (4)
- Biologic (8)
- Biosimilar (10)
- Biotech conferences (9)
- Biotechnology (96)
- Biotechnology Industry Organization (8)
- BLA (3)
- Books (1)
- Cancer (17)
- Cardiovascular (2)
- China (4)
- chronic fatigue syndrome (3)
- Clinic (4)
- clinical study report (1)
- Clinical Trial (16)
- Clinical Trial Design (1)
- Collaboration (5)
- Complete Response Letter (4)
- Congress (2)
- Deals (6)
- Diabetes (1)
- DNA (2)
- Drug Approval (15)
- drug importation (1)
- embryonic stem cell research (1)
- emerging markets (2)
- epilepsy (1)
- ethics (1)
- European Medicines Agency (5)
- evolution (1)
- executive salaries (1)
- FDA (25)
- Financing (24)
- FOB (1)
- Follow-on biologic (2)
- FTC (1)
- Gene Therapy (5)
- generic (2)
- genetics (4)
- Genomics (7)
- Healthcare reform (4)
- HIV (1)
- immunotherapy (4)
- IND (2)
- Investigational New Drug Application (3)
- IPO (4)
- License (2)
- M&A (6)
- multidrug resistance (1)
- mutation (1)
- National Institutes of Health (1)
- NDA (3)
- neurology (3)
- neuroprostheses (1)
- neuroprosthetic (1)
- New Drug Application (7)
- Obesity (1)
- OIG (1)
- Orphan disease (8)
- pandemic (1)
- partnering (1)
- patent cliff (2)
- Patents (5)
- PDUFA (4)
- Personalized medicine (4)
- Pharmaceutical (21)
- Phase I (5)
- Phase II (4)
- Phase III (6)
- Pipeline (6)
- Preclinical (2)
- prostate cancer (1)
- Rare disease (3)
- Reimbursement (9)
- REMS (1)
- RNAi (2)
- SEC (1)
- sequestration (1)
- Series A (1)
- Shareholder value (1)
- siRNA (2)
- Stem cell (2)
- Summer reading (1)
- Supplemental new drug application (2)
- TB (1)
- traumatic brain injury (1)
- Tuberculosis (2)
- Type 2 Diabetes (1)
- Uncategorized (14)
- Vaccine (4)
- venture captial (7)
- Video (5)
- virus (2)
Tags
ABH
ASCO
BIO
Biotechnology Industry Organization
bioworld
BRIC
Celgene Corp
CEO
CFS
China
Clovis Oncology Inc
Cynthia Robbins Roth
Day Four
Day Three
Day Two
Dendreon Corp
DNA
EST
EU
FDA
HCV
HIV
IPO
Janssen Labs
Mama Namibia
Mari Serebrov
MBA
Morgan Healthcare Conference
New York
New York Times
NIH
Nobel Prize
PDUFA
Pfizer Inc
PR
RNA
Roche
ROI
San Diego
San Francisco
Seattle Genetics Inc
SEC
UK
VC
Vivus Inc
Recommended Blogs
Recommended Organizations
Twitter Updates
Part of Thompson Media Group LLC: Thompson.com | Sheshunoff.com | ASPratt.com | BioWorld.com | CMEweb.com | Performanceweb.org | ASMIweb.com
© Copyright 2013 | BioWorld
© Copyright 2013 | BioWorld
Join the Conversation